All In Biotech

Drug Trial Radar · NCT05879718

A Study to Learn About the Study Medicine (PF-06823859) in Adults With Active CLE or SLE With Skin Symptoms.

A PHASE 2, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE CLINICAL EFFECT, PHARMACODYNAMIC, PHARMACOKINETIC AND SAFETY PROFILE OF PF 06823859 IN ADULT PARTICIPANTS WITH ACTIVE CLE OR SLE WITH CUTANEOUS MANIFESTATIONS

Last checked: Nov 20, 2026Latest source record: Aug 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

8

Actual

Start

Jul 7, 2023

Primary completion

Jun 5, 2025

Study completion Nov 18, 2025

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
May 30, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to learn about the effects, safety and how PF-06823859 is processed in adults with cutaneous lupus erythematosus (CLE) or systemic lupus erythematosus (SLE) showing some skin symptoms. This study is seeking for participants who: * are adults of 18 years of age or older. * are confirmed to have CLE or SLE with involvement of the skin. * have a Cutaneous Lupus Erythematosus Disease Area and Severity Index activity (CLASI-A) score of at least 8. About 48 participants will be selected to receive active study medicine (PF-06823859) or placebo (an infusion without drug). About 32 are grouped to receive the active study medicine and 16 are to receive placebo. They will be receiving the treatments by intravenous infusion (injected directly into the veins). At week 16 all participants receiving the active study drug since day 1 and participants who have received placebo since day 1 and are not responding clinically will receive active study medication. Patients who have received placebo since Day 1 and who have had a clinical response will continue to receive placebo till week 40. All participants will have last follow-up visit at Week 60. The study will compare participants receiving PF-06823859 to participants who receive placebo. This will help us see if PF-06823859 is safe and effective to treat CLE or SLE with skin symptoms and improve participant's CLASI-A score. Participants will take part in this study for about 65 weeks. This includes up to a 5-week selection period, a 12-week Q4Wk treatment period, a 36-week Q8Wk treatment period, and a 12-week follow-up period.

Conditions

  • Lupus Erythematosus, Systemic
  • Lupus Erythematosus, Cutaneous

Interventions

  • PlaceboDrug

    Placebo (intravenous infusion)

  • PF-06823859Drug

    PF-06823859 (intravenous infusion)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Type 1 Interferon (IFN) Gene Signature (GS) Score in Lesional Skin at Week 12Time frame: Baseline, Week 12

Locations

19 sites in 4 countries. Site status is shown where the registry gives one.

  • The Kirklin Clinic of UAB Hospital

    Birmingham, Alabama

  • University of Alabama at Birmingham - School of Medicine

    Birmingham, Alabama

  • University of Alabama at Birmingham, Department of Dermatology

    Birmingham, Alabama

  • The University of Alabama at Birmingham

    Birmingham, Alabama

  • Mayo Clinic Hospital

    Phoenix, Arizona

  • Mayo Clinic in Arizona - Scottsdale

    Scottsdale, Arizona

  • Dermatology Research Associates

    Los Angeles, California

  • Emory University

    Atlanta, Georgia

  • The University of Kansas Hospital

    Kansas City, Kansas

  • University of Kansas Medical Center

    Kansas City, Kansas

  • Cleveland Clinic Foundation

    Cleveland, Ohio

  • DermEffects

    London, Ontario, Canada

  • Dermatology on Bloor - Research Toronto

    Toronto, Ontario, Canada

  • Whitby Health Centre

    Whitby, Ontario, Canada

  • Dermatological and Venereological Hospital Andreas Syggros

    Athens, Greece

  • University General Hospital "ATTIKON" - General Hospital of West Attica "H AGIA VARVARA"

    Chaïdári, Attikí, Greece

  • Ionos Dragoumi 5 Kaisariani

    Kaisarianí, Attikí, Greece

  • Hospital Universitario 12 de Octubre

    Madrid, Spain

  • Hospital Universitario Virgen Del Rocio

    Seville, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.